Abstract: Objective：Compare with the efficacy of intravenous chemotherapy and intraperitoneal chemotherapy in two different administration methods of advanced epithelial ovarian cancer. Methods：Select 62 patients who were diagnosed advanced epithelial ovarian cancer in the Tianjin NO.5 Central Hospital, the patients were randomly divided into intravenous chemotherapy and intraperitoneal perfusion group. Intravenous drip group scheme：paclitaxel 135 mg/m2 intravenous infusion in the first day，cisplatin after 24 h 75 mg/m2 intravenously. Intraperitoneal perfusion group scheme：paclitaxel intravenous infusion of 135 mg/m2 in the first day，24 h after cisplatin 100 mg/m2 intraperitoneal，and paclitaxel 60 mg/m2 intraperitoneal perfusion in the eighth day. All patients were followed，compared short-term and long-term efficacy and adverse reactions of the two groups patients respectively. Results：The tumor remission rate in intraperitoneal perfusion group was higher than the intravenous drip group, but the difference wasn′t statistically significant（P＞0.05）；in the compasion of the progression-free survival and 2-year survival rates between the two groups，the intraperitoneal perfusion group was significantly higher than that of intravenous infusion group，difference was statistically significant（P＜0.01）；the adverse reaction of intraperitoneal perfusion group was higher, but only in anemia, liver function damage and the incidence of neurotoxicity which the difference between the two groups was significant (P＜0.05), the other adverse reaction incidence rate between the 2 groups was similar. Conclusions：Intraperitoneal perfusion chemotherapy can effectively improve PFS and 2-year survival rates of patients with advanced epithelial ovarian cancer and also improve patient outcomes.

Key words: Ovarian neoplasms, Cisplatin, Chemotherapy, cancer, regional perfusion, Injections, Drug therapy, combination, Paclitaxel